Binnopharm Group has increased export production at its Zelenograd site by almost three times

In the first quarter of 2025, the Zelenograd production site of Binnopharm Group increased its output of medicinal products for export by almost three times compared to the same period in 2024. 41% of the total volume of products manufactured by the Binnopharm plant over three months is intended for export to foreign markets. We manufacture inhalation aerosol medications for the CIS markets to treat and relieve asthma and chronic lung disease symptoms.

Anatoly Yaglenko, Corporate Director of Production, Binnopharm Group: «We focus on demand for our products not only in Russia, but also in foreign markets. The increase in the volume of export-oriented products results from our commitment to expanding the company’s presence in the international market. The plant’s capacity allows us to increase production volumes and launch new products at the site».

The Binnopharm production site, located in Zelenograd, is one of Russia’s largest full-cycle biopharmaceutical complexes. It produces drugs in various therapeutic groups and forms (solutions, tablets, suppositories, and aerosols). In 2024, the plant produced more than 5 million packages of drugs.